Literature DB >> 2033393

Human cytotoxic T cell responses to vaccinia virus vaccination.

S Graham1, C P Green, P D Mason, L K Borysiewicz.   

Abstract

Recombinant vaccinia viruses have been proposed as live virus vectors in man to generate both specific humoral and cellular immune responses. The generation of such responses following revaccination was followed in five normal volunteers. All five showed elevated (35- to 6500-fold) vaccinia virus-specific IgG by 14 days post-vaccination, following uncomplicated vaccination by dermal scarification. Four of the five had elevated total serum immunoglobulins with increased spontaneous and pokeweed mitogen-induced immunoglobulin production. Major histocompatibility complex class I-restricted vaccinia virus-specific cytotoxic T lymphocytes (CTLs) were not detected either directly, from peripheral blood mononuclear cells, or following secondary in vitro stimulation, even by limiting dilution analysis. These studies would suggest that vaccination with recombinant vaccinia viruses may provide an insufficient stimulus to the generation of CTLs in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033393     DOI: 10.1099/0022-1317-72-5-1183

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  3 in total

1.  Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.

Authors:  G Ferrari; W Humphrey; M J McElrath; J L Excler; A M Duliege; M L Clements; L C Corey; D P Bolognesi; K J Weinhold
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

2.  Vaccinia virus-specific human CD4+ cytotoxic T-lymphocyte clones.

Authors:  R A Littaua; A Takeda; J Cruz; F A Ennis
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

3.  Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans.

Authors:  W E Demkowicz; F A Ennis
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.